Acurx Pharmaceuticals Q4 EPS $(0.37) Misses $(0.26) Estimate
Portfolio Pulse from Benzinga Newsdesk
Acurx Pharmaceuticals (NASDAQ:ACXP) reported a Q4 EPS loss of $(0.37), missing the consensus estimate of $(0.26) by 42.31%. This represents a 32.14% increase in losses compared to the same period last year.
March 18, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acurx Pharmaceuticals reported a larger than expected Q4 loss, missing analyst estimates.
Missing the earnings estimate by a significant margin (42.31%) and reporting a larger loss compared to the previous year could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100